GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (NAS:BIOL) » Definitions » Cyclically Adjusted PB Ratio

Biolase (Biolase) Cyclically Adjusted PB Ratio : 0.00 (As of Apr. 29, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Biolase Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Biolase's current share price is $0.148. Biolase's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $2,628.10. Biolase's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Biolase's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Biolase's highest Cyclically Adjusted PB Ratio was 6.13. The lowest was 0.01. And the median was 1.34.

BIOL's Cyclically Adjusted PB Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.11
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biolase's adjusted book value per share data for the three months ended in Dec. 2023 was $-0.072. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2,628.10 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biolase Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biolase's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase Cyclically Adjusted PB Ratio Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.30 0.30 0.02 -

Biolase Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 - - -

Competitive Comparison of Biolase's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, Biolase's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biolase's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biolase's Cyclically Adjusted PB Ratio falls into.



Biolase Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biolase's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.148/2628.1
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biolase's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Biolase's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.072/129.4194*129.4194
=-0.072

Current CPI (Dec. 2023) = 129.4194.

Biolase Quarterly Data

Book Value per Share CPI Adj_Book
201403 2,805.296 99.695 3,641.723
201406 904.361 100.560 1,163.907
201409 2,967.647 100.428 3,824.350
201412 8,496.162 99.070 11,098.935
201503 7,485.484 99.621 9,724.515
201506 6,261.089 100.684 8,048.023
201509 5,311.290 100.392 6,847.034
201512 5,025.202 99.792 6,517.116
201603 4,353.427 100.470 5,607.800
201606 3,820.968 101.688 4,862.982
201609 4,524.306 101.861 5,748.353
201612 3,830.729 101.863 4,867.048
201703 3,183.016 102.862 4,004.814
201706 3,904.938 103.349 4,889.977
201709 3,266.204 104.136 4,059.228
201712 3,572.650 104.011 4,445.393
201803 3,044.811 105.290 3,742.611
201806 2,474.515 106.317 3,012.226
201809 1,977.724 106.507 2,403.190
201812 1,315.421 105.998 1,606.079
201903 818.427 107.251 987.598
201906 433.371 108.070 518.987
201909 -121.412 108.329 -145.049
201912 29.968 108.420 35.772
202003 -385.091 108.902 -457.645
202006 64.995 108.767 77.336
202009 368.548 109.815 434.342
202012 253.647 109.897 298.706
202103 560.335 111.754 648.907
202106 549.289 114.631 620.150
202109 494.014 115.734 552.429
202112 409.533 117.630 450.580
202203 333.657 121.301 355.988
202206 315.317 125.017 326.421
202209 194.035 125.227 200.532
202212 63.321 125.222 65.444
202303 30.987 127.348 31.491
202306 6.500 128.729 6.535
202309 0.147 129.860 0.147
202312 -0.072 129.419 -0.072

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biolase  (NAS:BIOL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biolase Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biolase's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolase (Biolase) Business Description

Traded in Other Exchanges
Address
27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
Executives
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Lord Jonathan T Md director 500 WEST MAIN ST., LOUISVILLE KY 40202
Jennifer Bright officer: Chief Financial Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Steven Sandor officer: Chief Operating Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Kenneth P. Yale director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
John R Beaver director, officer: President & CEO C/O STERLING CHEMICALS INC, 1200 SMITH STREET, HOUSTON TX 77002
Kathleen T Oloughlin director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Somerman Martha J. Dds, Phd director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Summerhays Carol Gomez Dds director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Family Foundation Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Larry N Feinberg 10 percent owner C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Michael Ditolla director 3299 CAMBRIDGE AVE, BRONX NY 10463